Clinical Trials Logo

Newly Diagnosed Glioblastoma clinical trials

View clinical trials related to Newly Diagnosed Glioblastoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05864534 Recruiting - Clinical trials for Glioblastoma Multiforme

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Start date: January 31, 2024
Phase: Phase 2
Study type: Interventional

Brain tumor treatment is hampered by the blood-brain barrier (BBB). This barrier prevents drugs carried in the bloodstream from getting into the brain. If the BBB can be opened, making it temporarily more permeable, drugs may able to better reach the brain tumor. In this trial we will implant a novel device with 9 ultrasound emitters, allowing temporary and reversible opening of the BBB to maximize brain penetration of drugs that modulate the immune system. The device will be implanted after radiation is completed. Immune modulating drugs will be given every 3 weeks in conjunction with activation of the device to open the BBB. The objectives of this trial are to establish whether it is safe and feasible to administer immune modulating drugs in this manner, and identify whether the treatment is effective in treating glioblastoma.

NCT ID: NCT05447195 Recruiting - Clinical trials for Newly-diagnosed Glioblastoma

Phase 2 Study of CAN008 in Subjects With GBM

Start date: October 10, 2021
Phase: Phase 2
Study type: Interventional

This is a multi-center, randomized, double-blind, placebo-controlled Phase 2 study whose objectives are to evaluate the clinical efficacy and safety of CAN008 plus TMZ during and after radiation therapy in newly-diagnosed subjects with glioblastoma who have undergone surgical excision.

NCT ID: NCT05380349 Recruiting - Clinical trials for Newly Diagnosed Glioblastoma

Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma

Start date: April 19, 2024
Phase: Early Phase 1
Study type: Interventional

Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.

NCT ID: NCT05235737 Recruiting - Clinical trials for Newly Diagnosed Glioblastoma

The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab

PIRG
Start date: March 1, 2022
Phase: Phase 4
Study type: Interventional

To evaluate the short-term and longer-term safety, tolerability, and effectiveness of neoadjuvant and adjuvant Pembrolizumab on top of standard therapy (Stupp protocol) in patients with Glioblastoma Multiforme (GBM). Randomized comparison of safety, tolerability, and clinical efficacy of (1) neoadjuvant and adjuvant Pembrolizumab (on top of Stupp protocol, n=12 patients), (2) neoadjuvant Pembrolizumab (on top of Stupp protocol, n=12 patients), and (3) standard of care (Stupp protocol only, n=12 patients). Immuno-PET examination will be performed before and after surgery in all patients.

NCT ID: NCT04840069 Recruiting - Clinical trials for Newly Diagnosed Glioblastoma

Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma

Start date: June 7, 2021
Phase: Phase 2
Study type: Interventional

The purpose of the this study is to see if the use of a PET scan with 18F-fluciclovine (PET or Fluciclovine PET) in addition to the normal radiation planning imaging procedures (MRI and CT scan) will help determine the areas where the radiation therapy is to be delivered. It is also a goal of the study to determine if subjects live longer when treatment plans for radiation therapy are designed using a Fluciclovine PET scan, as well as MRI and CT scans. We will also collect information on if and where the tumor returns. Information on the side effects from the two different treatment planning imaging methods will also be collected. 18F-Fluciclovine is an FDA-approved radioactive diagnostic agent that is injected into the patient and then taken up by cancer cells, which can then be visualized with a PET/CT scan. 18F-Fluciclovine is FDA approved for the detection of recurrent prostate cancer, but is still investigational for the purposes of this study.

NCT ID: NCT04478279 Recruiting - Breast Cancer Clinical Trials

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Start date: July 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.

NCT ID: NCT04477200 Recruiting - Clinical trials for Recurrent Glioblastoma

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Start date: August 5, 2020
Phase: Phase 1
Study type: Interventional

This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.

NCT ID: NCT04474353 Recruiting - Glioblastoma Clinical Trials

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

Start date: May 21, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of the combination therapy of TTFields + SRS+ Temozolomide (TMZ) for newly diagnosed glioblastoma (GBM).